BRIEF-Amgen Says Repatha Cuts Risk Of First Major Adverse Cardiovascular Events By 25% In Phase 3 Vesalius-CV Trial
Reuters
Nov 08
BRIEF-Amgen Says Repatha Cuts Risk Of First Major Adverse Cardiovascular Events By 25% In Phase 3 Vesalius-CV Trial
Nov 8 (Reuters) - Amgen Inc AMGN.O:
AMGEN: REPATHA CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN PHASE 3 VESALIUS-CV TRIAL
AMGEN: STUDY ALSO SHOWS 36% REDUCTION IN RISK OF HEART ATTACK
Source text: https://tinyurl.com/33ptdxf5
Further company coverage: AMGN.O
((Reuters.briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.